Abstract
British Journal of DermatologyVolume 181, Issue 3 p. 646-646 CorrigendumFree Access Corrigendum This article corrects the following: Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR) Z.Z.N. Yiu, D.M. Ashcroft, I. Evans, K. McElhone, M. Lunt, C.H. Smith, S. Walton, R. Murphy, N.J. Reynolds, A.D. Ormerod, C.E.M. Griffiths, R.B. Warren, , Volume 180Issue 2British Journal of Dermatology pages: 329-337 First Published online: October 21, 2018 First published: 01 September 2019 https://doi.org/10.1111/bjd.18352AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat In the article by Yiu et al, on page 331 it states that 844 patients were not included; three emigrated, 785 withdrew consent and 56 did not complete their questionnaire. Similarly, on page 335 it states that a total of 844 registered patients were classified as dropping out owing to lack of follow-up. Of these patients, 92·5% (785 patients) discontinued the study owing to withdrawal of consent. The correct reasons are 80.7% (681 patients) had not reached their first follow-up, 15.7% (133 patients) did not attend their follow-up clinics, and 3.6% (30 patients) moved to an unknown area or hospital or withdrew consent. The authors apologise for the error. Reference Reference 1Yiu ZZN, Ashcroft DM, Evans I et al. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol 2019; 180: 329– 37. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar Volume181, Issue3September 2019Pages 646-646 ReferencesRelatedInformation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
